Breaking Finance News

Mirati Therapeutics (NDAQ:MRTX) stock price target increased to $9.00, issued a report today by Leerink Swann

Yesterday Mirati Therapeutics (NDAQ:MRTX) traded 134.74% higher at $11.15. The company’s 50-day moving average is $5.03 and its 200-day moving average is $4.45. The last closing price is up 150.72% from the 200-day moving average, compared to the S&P 500 which has increased 0.04% over the same time period. 18,883,793 shares of the stock traded hands, up from an average trading volume of 189,209

In a report released on 9/15/2017 Leerink Swann increased the stock price target of Mirati Therapeutics (NDAQ:MRTX) from $7.00 to $9.00 indicating a possible downside of -0.19%.

Previously on 6/13/2017, Jefferies & Co reported on Mirati Therapeutics (NDAQ:MRTX) increased the target price from $0.00 to $4.50. At the time, this indicated a possible upside of 0.34%.

See Chart Below

Mirati Therapeutics (NDAQ:MRTX)

Mirati Therapeutics has a 52 week low of $2.70 and a 52 week high of $11.35 The company’s market cap is currently $0.

In addition to Leerink Swann reporting its stock price target, a total of 7 brokers have issued a report on the company. The average stock price target is $30.43 with 4 brokers rating the stock a strong buy, 2 brokers rating the stock a buy, 1 broker rating the stock a hold, 0 brokers rating the stock a underperform, and finally 0 brokers rating the stock a sell.

General Information About Mirati Therapeutics (NDAQ:MRTX)

Mirati Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of oncology products. The companyÂ’s clinical stage product candidates include glesatinib, an orally-bioavailable, potent, small molecule kinase inhibitor that is in Phase II clinical trials for the treatment of non-small cell lung cancer (NSCLC) patients with genetic alterations of MET; and in Phase Ib clinical trials in patients with genetic alterations of MET and Axl in NSCLC and other solid tumors. Its clinical stage product candidates also comprise sitravatinib, an orally-bioavailable, potent, small molecule spectrum-selective kinase inhibitor, which is in Phase II clinical trials for the treatment of solid tumors, such as NSCLC and metastatic Renal Cell Carcinoma, as well as in Phase Ib clinical trials to treat NSCLC patients with RET, CHR4q12, CBL, and AXL genetic alterations; and mocetinostat, an orally administered spectrum-selective Class 1 histone deacetylase inhibitor, which is in Phase Ib/II clinical trials in combination with durvalumab for the treatment of patients with NSCLC. The company has a collaboration agreement with Foundation Medicine, Inc. and Guardant Health, Inc. to explore development of their platforms as companion diagnostics for glesatinib. Mirati Therapeutics, Inc. is headquartered in San Diego, California.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.